Teva To Market Generic Drug Plavix With Annual Sales Of $6.8B

Teva has received approval from the US Food and Drug Administration (FDA) to market a generic version of Plavix (Clopidogrel) developed by pharmaceutical company Sanofi. Total US sales of the drug, designed to prevent blood clotting, totaled $ 6.8 billion in the last 12 months, according to medical research agency IMS. In 2007, Plavix was the second-most prescribed drug in the world, after Lipitor (Atorvastatin).